REFERENCES
1. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and
long-term survival in patients with initially unexplained
cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
DOI: 10.1056/NEJM200004133421502
2. Avila M.S., Siqueira S.R.R., Ferreira S.M.A., Bocchi E.A. Prevention
and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist
Debakey Cardiovasc J. 2019;15:267-273. DOI: 10.14797/mdcj-15-4-267
3. Cowie M.R., Anker S.D., Cleland J.G.F., et al. Improving care for
patients with acute heart failure: before, during and after
hospitalization. ESC heart failure. 2014;1:110-145. DOI:
10.1161/CIRCOUTCOMES.120.006693
4. Yancy C.W., Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused
Update of the 2013 ACCF/AHA Guideline for the Management of Heart
Failure: A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart
Failure Society of America. J Card Fail. 2017;23:628-651. DOI:
10.1161/CIR.0000000000000509
5. De Ferrari G.M., Mazzuero A, Agnesina L, et al. Favourable effects of
heart rate reduction with intravenous administration of ivabradine in
patients with advanced heart failure. Eur J Heart Fail.2008;10:550-555.
DOI: 10.1016/j.ejheart.2008.04.005
6. Franke J, Schmahl D, Lehrke S, et al. Adjuvant Use of Ivabradine in
Acute Heart Failure due to Myocarditis. Case Rep Med.2011:203690.
DOI: 10.1155/2011/203690
7. Chiu M.H., Howlett J.G., Sharma N.C. Initiation of ivabradine in
cardiogenic shock. ESC heart failure. 2019;6:1088-1091.
DOI: 10.1002/ehf2.12499
8. Izco M.P., Ramirez-Carracedo R, Navarro I.H., et al. Ivabradine in
acute heart failure: Effects on heart rate and hemodynamic parameters in
a randomized and controlled swine trial. Cardiol J.2020;27:62-71.
DOI: 10.5603/CJ.a2018.0078
9. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of
anthracycline cardiotoxicity and improvement with heart failure therapy.Circulation. 2015;131:1981-1988. DOIi:
10.1161/CIRCULATIONAHA.114.013777
10. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate
reduction induced by the selective I(f) current inhibitor ivabradine
improves left ventricular function and intrinsic myocardial structure in
congestive heart failure. Circulation. 2004;109:1674-1679.
DOI: 10.1161/01.CIR.0000118464.48959.1C
11. Custodis F, Schirmer S.H., Baumhakel M, Heusch G, Bohm M, Laufs U.
Vascular pathophysiology in response to increased heart rate. J Am
Coll Cardiol. 2010;56:1973-1983. DOI: 10.1152/physrev.00042.2012
12. Reil J.C., Tardif J.C., Ford I, et al. Selective heart rate
reduction with ivabradine unloads the left ventricle in heart failure
patients. J Am Coll Cardiol. 2013;62:1977-1985. DOI:
10.1016/j.jacc.2013.07.027
13. Xie M, Huang H.L., Zhang W.H., et al. Increased
sarcoplasmic/endoplasmic reticulum calcium ATPase 2a activity underlies
the mechanism of the positive inotropic effect of ivabradine. Exp
Physiol. 2020;105:477-488.
DOI: 10.1113/EP087964
14. Izumida T, Imamura T, Nakamura M, Fukuda N, Kinugawa K. How to
consider target heart rate in patients with systolic heart failure.ESC heart failure. 2020;7:3231-3234. DOI: 10.1002/ejhf.1054